Forest/Lipha Campral
Executive Summary
FDA approves Campral (acamprosate) July 29 for the treatment of "alcohol dependent individuals seeking to continue to remain alcohol-free after they have stopped drinking." Campral should be used as one part of a comprehensive alcoholism management program that includes "psychosocial support," FDA says in a July 29 "Talk Paper." Forest will launch the drug in the U.S. near the end of the year...
You may also be interested in...
Campral Clears FDA For Alcohol Dependence: Renal Study Part Of Phase IV
Merck KGaA subsidiary Lipha will determine appropriate Campral dosing in patients with severe renal impairment as a postmarketing commitment following FDA approval of the alcoholism therapy
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.